We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Regeneron Pharmaceuticals, Inc. (REGN) Might Be a Diamond in the Rough
Read MoreHide Full Article
It commonly happens in stock investing that investors miss the chance of buying winning stocks that they knew would stand out. Before they take the plunge, others get to know the hidden potential and enter into these stocks, pushing them out of reach.
So, instead of repenting, spotting the off-the-radar potential winners and immediately investing in them could be a smart decision.
One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Regeneron Pharmaceuticals, Inc. (REGN - Free Report) . This Medical - Biomedical and Geneticsindustry stock has actually seen estimates rise over the past month for the current fiscal year by about 15%. But that is not yet reflected in its price, as the stock lost 11% over the same time frame.
Regeneron Pharmaceuticals, Inc. Price and Consensus
You should not be concerned about the price remaining muted going forward. This year’s expected earnings growth over the prior year is 67.1%, which should ultimately translate into price appreciation.
So if you are looking for a stock flying under-the-radar that is well-equipped to bounce down the road, make sure to consider Regeneron Pharmaceuticals. Solid estimate revisions and an impressive Zacks Rank suggest that better days may be ahead for REGN and that now might be an interesting buying opportunity.
Zacks' 10-Minute Stock-Picking Secret
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month.
Image: Bigstock
Why Regeneron Pharmaceuticals, Inc. (REGN) Might Be a Diamond in the Rough
It commonly happens in stock investing that investors miss the chance of buying winning stocks that they knew would stand out. Before they take the plunge, others get to know the hidden potential and enter into these stocks, pushing them out of reach.
So, instead of repenting, spotting the off-the-radar potential winners and immediately investing in them could be a smart decision.
One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Regeneron Pharmaceuticals, Inc. (REGN - Free Report) . This Medical - Biomedical and Geneticsindustry stock has actually seen estimates rise over the past month for the current fiscal year by about 15%. But that is not yet reflected in its price, as the stock lost 11% over the same time frame.
Regeneron Pharmaceuticals, Inc. Price and Consensus
Regeneron Pharmaceuticals, Inc. Price and Consensus | Regeneron Pharmaceuticals, Inc. Quote
You should not be concerned about the price remaining muted going forward. This year’s expected earnings growth over the prior year is 67.1%, which should ultimately translate into price appreciation.
And if this isn’t enough, REGN currently carries a Zacks Rank #1 (Strong Buy) which further underscores the potential for its outperformance (See the performance of Zacks' portfolios and strategies here: About Zacks Performance).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
So if you are looking for a stock flying under-the-radar that is well-equipped to bounce down the road, make sure to consider Regeneron Pharmaceuticals. Solid estimate revisions and an impressive Zacks Rank suggest that better days may be ahead for REGN and that now might be an interesting buying opportunity.
Zacks' 10-Minute Stock-Picking Secret
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month.
Learn the secret >>